Madueke-Laveaux OS

No ORCID on file · 6 papers in corpus
review 2026
Cells ·doi:10.3390/cells15161469

Uterine fibroids, the most common tumors in reproductive-age women, remain without a defined precursor tissue state. Unlike cervical dysplasia preceding cervical cancer, or colonic polyps preceding colorectal malignancy, no equivalent "at-r…

case-report 2026
International journal of fertility & sterility ·doi:10.22074/ijfs.2026.2069660.1938

Disseminated peritoneal leiomyomatosis (DPL) is a rare condition in which fibroids diffusely grow in extrauterine locations. Given its low prevalence, the literature is limited, making evidence-based treatment particularly challenging, espe…

observational 2025
International journal of women's health ·doi:10.2147/ijwh.s523846

BACKGROUND: Limited evidence is available regarding preferences of women with uterine fibroids (UF) and treating healthcare providers (HCPs) regarding treatment attributes; this evidence could contribute to patient-centered shared decision-…

2024
Journal of medical imaging (Bellingham, Wash.) ·doi:10.1117/1.jmi.11.5.054501

SignificanceUterine fibroids (UFs) can pose a serious health risk to women. UFs are benign tumors that vary in clinical presentation from asymptomatic to causing debilitating symptoms. UF management is limited by our inability to predict UF…

review 2023
F&S reports ·doi:10.1016/j.xfre.2022.11.008

Treatment of heavy menstrual bleeding associated with uterine fibroids (UF) is evolving. Historically, treatment options were limited to predominantly invasive surgery; today, conservative and novel oral medical treatments are widely availa…

review 2023
Journal of endometriosis and uterine disorders ·doi:10.1016/j.jeud.2023.100018

Uterine fibroids (UFs; leiomyoma) are the most common benign neoplastic threat to women worldwide, exacting an immense personal burden on female health and a monetary expense to the healthcare system estimated in the hundreds of billions of…